Soligenix employs its synthetic hypericin platform to create a versatile therapeutic approach that can be adapted to multiple dermatologic conditions. This strategy reduces time and cost by reusing core molecular mechanisms rather than designing new compounds for each indication.

HyBryte is currently in development for both cutaneous T-cell lymphoma and psoriasis, marking the platform's first dual therapeutic application. The company is progressing through formulation and early-stage studies to demonstrate safety and skin-targeted efficacy.

Platform-based development offers efficiency gains and risk management by leveraging a validated mechanism across indications. Soligenix aims to de-risk its pipeline and accelerate clinical milestones, potentially enhancing investor confidence as multiple studies advance.